
The CEO and co-founder of the Peggy Lillis Foundation discusses highlights from the organization's 2024 National C diff Advocacy Summit.

The CEO and co-founder of the Peggy Lillis Foundation discusses highlights from the organization's 2024 National C diff Advocacy Summit.

Community pharmacists’ influence increases the likelihood of patients safely disposing unused medications and keeping them out of harm’s reach.

Tovorafenib is the first systemic therapy to be approved for the treatment of pediatric patients who have low-grade glioma with BRAF rearrangements or fusions.

Shawn Riser Taylor, PharmD, CPP, CDCES, discusses the challenges and process of providing health care in a rural area of Guachipilincito in Honduras.

Pharmacists working with long-term care centers benefit from streamlined billing to support and build patient trust.


The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

On this month's episode Laura Gillespie, PharmD, discusses her paper “Impact of Pharmacist-Led Initiatives on Health Care–Associated Clostridioides difficile Rates.”

The severity of RSV disease among adults further highlights how crucial vaccine polices and recommendations are.

The findings emphasize a need for guideline-based care delivery for patients with severe asthma, particularly for patients who are facing social disparities within health care.

Dostarlimab plus chemotherapy is the only immuno-oncology-based therapy that showed statistically significant and clinically meaningful survival benefit in the overall patient population.

This year’s event from June 20 to 21, 2024, in Austin, Texas, will offer 4.25 BCOP CE hours.

Naloxone hydrochloride (Amneal Pharmaceuticals Inc) is the generic equivalent to OTC Narcan (Emergent).

Advances, challenges, and promising innovations emerge.

A 76% lower risk was displayed with adjuvant alectinib compared to chemotherapy treatment for non–small cell lung cancer.

Tune into this episode of “Public Health Matters” to learn about Dr. Pauline K. Long and her entrepreneurship journey, as well as how she creates meaningful impacts on patients in marginalized communities and within public health.

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.

Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.

Multiple state and federal laws since the COVID-19 pandemic highlight the growing role of technicians

The use of artificial intelligence and real-time symptom monitoring integrate effectiveness of prescription digital therapeutics for mental health issues

Carefully checking every piece of information and proofreading for accuracy is crucial to ensure patient safety

Pharmacists play a key role in psychiatric medication overdose situations

Successful integration demands overcoming various hurdles.

Laura Gillespie, PharmD, discusses some of the financial benefits of having a pharmacist focused on antimicrobial stewardship efforts in a health system.

Exploring challenges and opportunities in developing personalized treatments for schizophrenia

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

The AAN speaker highlights what health care providers need to know when treating migraines in populations on hormone therapy, as well as how hormones can influence migraines.

With migraine as a leading disability for those under the age of 50, treatment options for migraine should be personalized to the patient and their needs.